在帕金森病的老鼠模型中,巴利多他拉米回路选择性操纵改善了运动症状
Jacob Jackson1, Hannah Loughlin1, Chloe Looman1
1Department of Biomedical Engineering, Michigan Technological University, Houghton, Michigan 49931.
概括
在老鼠内细胞核 (EP) 中高频深度大脑刺激 (DBS) 改善了帕金森病 (PD) 运动症状. 这表明异常的大脑电路振荡,而不仅仅是发射率,是PD治疗的关键目标.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学工程 生物医学工程
背景情况:
- 深度大脑刺激 (DBS) 对于晚期帕金森病 (PD) 运动症状是有效的,通常针对内球体 (GPi).
- 对于DBS的精确治疗机制,特别是关于神经电路调制的准确治疗机制,我们仍然不完全理解.
- 鼠类内核 (EP) 作为灵长类GPi的功能同类,使其成为研究白DBS的合适模型.
研究的目的:
- 在PD模型中研究光遗传DBS在大鼠EP对运动症状的影响.
- 为了检查光遗传EP DBS如何调节EP和腹侧运动体 (VL) 中的神经活动和振荡模式.
- 阐明EP DBS在PD中的频率依赖行为效应背后的神经机制.
主要方法:
- 使用了一种单边的6-氧多巴胺 (6-OHDA) 损伤的 PD 鼠标模型.
- 在EP中使用各种频率 (5, 20, 75, 100, 130 Hz) 的光遗传刺激.
- 量化了运动症状的行为改善,并在EP和VL中进行单单元记录,以分析神经发射率和β频段振荡.
主要成果:
- 高频率 (75,100,130赫兹) 光遗传EP DBS显著降低了双侧转和改善了前肢的步伐.
- 低频刺激 (5,20 Hz) 没有显著的行为效应.
- 高频刺激,特别是130赫兹,增加了EP和VL中平均神经发射率,并减少了这两个区域的非正常β频段振荡,这表明电路级调制.
结论:
- 光遗传性EP DBS有效地改善了PD的老鼠模型中的运动缺陷.
- 高频EP DBS的治疗效益与减少皮体内回路中的异常振荡活动有关.
- 这些发现凸显了针对PD治疗的皮体内通路中通过光遗传DBS针对电路特异性振荡功能障碍的潜力.
相关概念视频
Parkinson's Disease: Treatment
198
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
198
Parkinson's Disease: Overview
452
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
452


